Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

(2019) Karim Fizazi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.

(2019) Bertrand F. TOMBAL et al.   JOURNAL OF CLINICAL ONCOLOGY

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

(2018) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

(2018) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure

(2018) Susan Slovin et al.   JAMA Oncology

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

(2015) Anu-Maarit Moilanen et al.   Scientific Reports

Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time

(2013) Matthew R. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET